Applying Artificial Intelligence & Machine Learning In Drug Discovery & Design — Dr. Ola Engkvist Ph.D., Head, Molecular AI, Discovery Sciences, R&D, AstraZeneca
Dr. Ola Engkvist is Head of Molecular AI in Discovery Sciences, AstraZeneca R&D (https://www.astrazeneca.com/).
Dr. Engkvist did his PhD in computational chemistry at Lund University followed by a postdoc at Cambridge University.
After working for two biotech companies Dr. Engkvist joined AstraZeneca in 2004. He currently leads the Molecular AI department, where the focus is to develop novel methods for ML/AI in drug design 0 productionalize the methods and apply the methods to AstraZeneca’s small molecules drug discovery portfolio.
Dr. Engkvist’s main research interests are deep learning based molecular de novo design, synthetic route prediction and large scale molecular property predictions, and he has published over 100 peer-reviewed scientific publications.
Dr. Engkvist is also adjunct professor in machine learning and AI for drug design at Chalmers University of Technology and a trustee of Cambridge Crystallographic Data Center.
Comments are closed.